Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharmascience international ltd. - cipru - duloxetinum - caps. gastrorez. - 30mg - antidepresive alte antidepresive

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharmascience international ltd. - cipru - duloxetinum - caps. gastrorez. - 60mg - antidepresive alte antidepresive

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare limited - marea britanie - sertralinum - compr. film. - 100mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare limited - marea britanie - sertralinum - compr. film. - 50mg - antidepresive inhibitori selectivi ai recaptarii serotoninei

Unió Europea - romanès - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Unió Europea - romanès - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamid - epilepsie - antiepileptice, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Unió Europea - romanès - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - medicamente pentru tratamentul bolilor osoase - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Moldàvia - romanès - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

msn laboratories pvt. limited - clofarabinum - concentrat pentru soluţie perfuzabilă - 20 mg/20 ml

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mcdermott laboratories limited t/a - irlanda - abacavirum+lamivudinum - compr. film. - 600mg/300mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii

Romania - romanès - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

zentiva, k.s. - republica ceha - abacavirum+lamivudinum - compr. film. - 600mg/300mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii